You are here

  • Home
  • Archive
  • Volume 11, Issue 2
  • Runx3-overexpression cooperates with ex vivo AKT inhibition to generate receptor-engineered T cells with better persistence, tumor-residency, and antitumor ability

Article metrics

Article menu
Immune cell therapies and immune cell engineering
Original research
Runx3-overexpression cooperates with ex vivo AKT inhibition to generate receptor-engineered T cells with better persistence, tumor-residency, and antitumor ability

 

Online download statistics by month:

Online download statistics by month: February 2023 to January 2026

AbstractFullPdf
Feb 202312312639
Mar 2023489491250
Apr 202316216354
May 2023119120111
Jun 202311111139
Jul 2023929335
Aug 202314214253
Sep 2023929434
Oct 2023818144
Nov 202312312458
Dec 2023989952
Jan 2024828460
Feb 2024484824
Mar 2024838358
Apr 202414314543
May 2024767851
Jun 2024767535
Jul 2024899049
Aug 2024555426
Sep 20246768227
Oct 2024636736
Nov 2024606236
Dec 202410010150
Jan 2025505124
Feb 202514814836
Mar 2025646445
Apr 2025727239
May 2025626244
Jun 2025545433
Jul 2025110
Jan 2026001
Total302530511686